3-(2-phenyl-2-oxoethyl)-1,2-dimethylimidazolium chloride | 121704-67-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2-phenyl-2-oxoethyl)-1,2-dimethylimidazolium chloride
• 英文别名: 2-(2,3-Dimethylimidazol-3-ium-1-yl)-1-phenylethanone;chloride
• CAS: 121704-67-4
• 化学式: C₁₃H₁₅N₂O*Cl
• 分子量: 250.728
• InChiKey: WIXGBSFWOMGBJH-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.49
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  25.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2-二甲基咪唑 、 2-溴苯乙酮 以 乙腈 为溶剂， 生成 3-(2-phenyl-2-oxoethyl)-1,2-dimethylimidazolium chloride
  参考文献：
  名称：

  Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides

  摘要：

  Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides. Compounds 2 and 3 produced reductions of ca. 40% 2 h after doses of 100 mg/kg po. Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion. Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.

  DOI：

  10.1021/jm00130a013

文献信息

• Method for treating fibrotic diseases or other indications IC
  申请人：Alteon, Inc.

  公开号：US20020068729A1

  公开（公告）日：2002-06-06

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种处理、改善或预防动物包括人类发明的指示的方法，包括给予公式I的化合物的有效量：1
• Method for treating fibrotic diseases or other indications with imidazolium agents
  申请人：Alteon, Inc.

  公开号：US20030176426A1

  公开（公告）日：2003-09-18

  Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: 1 wherein R 1 , R 2 , M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

  提供了一种治疗或改善动物（包括人类）发明的征兆的方法，通过给予公式I的有效量的化合物： 1 其中R 1 ，R 2 ，M，X和Z如上所述。还提供了一些咪唑啉化合物和包含咪唑啉化合物的药物组合物。
• Method for treating fibrotic diseases or other indications ID
  申请人：——

  公开号：US20020177586A1

  公开（公告）日：2002-11-28

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种在动物中（包括人类）治疗、改善或预防本发明指示的方法，其中包括给予化合物I的有效量：1。
• Method for treating fibrotic diseases or other indications IE
  申请人：——

  公开号：US20040235837A1

  公开（公告）日：2004-11-25

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种治疗、改善或预防发明所示迹象的方法，在动物中包括人类，该方法包括给予化合物I的有效剂量：1。
• Method for treating glaucoma IC
  申请人：——

  公开号：US20020160993A1

  公开（公告）日：2002-10-31

  Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I: 1

  提供了一种治疗、改善或预防青光眼、降低眼压或改善或缓解动眼调节的方法，包括在动物（包括人类）中给予化合物I的降低眼压或改善动眼调节的剂量。